Sanofi $2.2 billion vaccine deal comes alongside FDA setback

Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as it seeks to expand a vaccines business currently ...

Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult ...

Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger

Dynavax soared by 38.19 percent on Wednesday to close at $15.38 apiece as investors took heart from news that it was set to ...

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...